Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
June
30, 2006
Date
of
Report (Date of earliest event reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
State
of New
York
|
|
1-10113
|
|
11-0853640
|
(State
of Other Jurisdiction
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
|
of
Incorporation)
|
|
|
|
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d- 2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e- 4(c))
Item
8.01 Other
Events
On
June
30, 2006, the Registrant borrowed $335,000 pursuant to a Loan Agreement dated
as
of January 31, 2006 with Essex Woodlands Health Venture V, L.P., Care Capital
Investments II, L.P., Care Capital Offshore Investments II, L.P., Galen Partners
III, L.P., Galen Partners International III, L.P. and Galen Employee Fund III,
L.P. (collectively, the “VC Lenders”).
GCE
Holdings, LLC, which is controlled by the VC Lenders, beneficially owns
approximately 78% of the Registrant's outstanding common stock.
and has
the right to designate four directors (of which it has exercised the right
with
respect to three directors) to the Registrant’s Board of Directors.
Item
9.01 Financial
Statements and Exhibits
Exhibit
Number |
|
Description |
|
|
|
99.1 |
|
Press Release dated June 30, 2006 Announcing
Receipt of Interim Funding |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
ACURA
PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Peter
A.
Clemens |
|
Peter
A. Clemens |
|
Senior
Vice President & Chief Financial Officer |
|
|
Date: June
30, 2006 |
|
Exhibit
Index
Exhibit
Number |
|
Description |
|
|
|
99.1 |
|
Press Release dated June 30, 2006
Announcing
Receipt of Interim Funding |